AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has earned a consensus rating of “Buy” from the seven research firms that are presently covering the company. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $9.80.

ACRX has been the topic of a number of analyst reports. Roth Capital set a $15.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, March 6th. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, May 3rd. Stifel Nicolaus cut their price objective on shares of AcelRx Pharmaceuticals from $15.00 to $14.00 and set a “hold” rating on the stock in a report on Tuesday, March 14th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Monday, March 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $6.00 price objective on shares of AcelRx Pharmaceuticals in a report on Friday, March 3rd.

COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals Inc (ACRX) Given Average Recommendation of “Buy” by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/19/acelrx-pharmaceuticals-inc-acrx-given-average-recommendation-of-buy-by-brokerages-2.html.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) traded up 12.77% during mid-day trading on Friday, hitting $2.65. 1,049,828 shares of the stock were exchanged. The stock’s market capitalization is $120.26 million. AcelRx Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $4.08. The stock’s 50 day moving average price is $2.69 and its 200-day moving average price is $2.87.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.06. The firm had revenue of $3.11 million for the quarter, compared to analysts’ expectations of $2.36 million. AcelRx Pharmaceuticals had a negative return on equity of 232.39% and a negative net margin of 347.94%. On average, equities research analysts expect that AcelRx Pharmaceuticals will post ($1.09) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of ACRX. Wells Fargo & Company MN increased its position in AcelRx Pharmaceuticals by 196.3% in the third quarter. Wells Fargo & Company MN now owns 28,403 shares of the specialty pharmaceutical company’s stock worth $111,000 after buying an additional 18,818 shares in the last quarter. ING Groep NV increased its position in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares in the last quarter. Acadian Asset Management LLC increased its position in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares in the last quarter. Teachers Advisors LLC increased its position in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares in the last quarter. Finally, Oxford Asset Management boosted its stake in AcelRx Pharmaceuticals by 48.7% in the fourth quarter. Oxford Asset Management now owns 103,420 shares of the specialty pharmaceutical company’s stock worth $269,000 after buying an additional 33,866 shares during the last quarter. 35.01% of the stock is currently owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

5 Day Chart for NASDAQ:ACRX

Receive News & Ratings for AcelRx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.